Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT04963179

PREvention of Intrauterine Adhesion After Adhesiolysis With Novel Tri-block deGradable Polymer Film.

PREG2 is a randomized controlled trial that aims to evaluate efficacy in preventing intrauterine adhesion recurrence after hysteroscopic adhesiolysis of a novel intrauterine barrier film named Womed Leaf

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Gent UZ, Ghent, Belgium

Loading trial locations.

About this study

PREG2 is a prospective, multi-center, randomized, controlled, two arm clinical study. The objective is to evaluate the efficacy of Womed Leaf in preventing intrauterine adhesion recurrence after adhesiolysis compared to adhesiolysis alone.

The study will be performed on women with moderate or severe adhesions (AFS score >=5) scheduled for adhesiolysis. Indeed, the risk of intrauterine adhesion is very high (up to 60%) in this population of patients.

A follow-up diagnostic hysteroscopy will be performed 6-8 weeks after the adhesiolysis procedure to determine the presence and severity of IUAs according to the American Fertility Society and European Society of Gynecologic Endoscopy classification systems of adhesions. Fertility-related outcome will include live pregnancy at 1 year, 2 years and 3 years and will be reported as secondary endpoints. 154 women are planned to be included in the PREG2 study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women with moderate or severe intrauterine adhesions according to the AFS classification, i.e AFS score >=5, confirmed by hysteroscopy right before adhesiolysis
  • Scheduled for hysteroscopic adhesiolysis
  • Age above or equal to 18
  • Subjects who are willing to provide a written informed consent.
  • Subjects who can comply with the study follow-up (second look hysteroscopy) and other study requirements
  • Subjects who agree to refrain from intercourse or use a reliable form of barrier contraception to prevent unintended pregnancy until the follow-up hysteroscopy.
  • Subjects who agree to avoid all intrauterine devices (IUDs) until the follow-up hysteroscopy.

Exclusion criteria

Pre-operative criteria

  • Post menopause
  • Pregnant (confirmed by a positive pregnancy test) or lactating
  • Abnormal uterine cavity according to ESHRE classification I to V such as unicornis, bicornis, septate, duplex
  • Known or suspected endometrial hyperplasia
  • History of cervical or endometrial cancer
  • Active pelvic infection or history of pelvic peritonitis
  • History of endometrial ablation
  • Known contraindication or hypersensitivity to Womed Leaf component
  • Current participation in another clinical investigation that has not yet received the primary endpoint.
  • Any other condition that makes participation in the study contrary to the patient's best interests.

Intra-operative criteria, post adhesiolysis:

  • Perforation during adhesiolysis
  • Uterine depth < 5cm or > 10cm

Treatment and study plan

Womed Leaf

Device

Womed Leaf™ device is composed of a uterine anti-adhesion film pre-loaded inside a flexible inserter.

Womed Leaf™ is inserted in the uterine cavity by the gynecologist surgeon as a film folded into a 5 mm diameter flexible inserter. Once released, the film will unfold and swell into the uterine cavity to keep uterus walls separated. It is degraded and discharged naturally through the cervix and vagina.

Primary outcomes

  1. Efficacy - IUA Severity

    Time frame: At second look hysteroscopy between 4 and 8 weeks

    Change of AFS score between pre-adhesiolysis and second-look hysteroscopy (AFS) score

    The scale used to assess the severity of intrauterine adhesions is the American Fertility Society score. It is a 12 points composite score that adds-up 3 subcomponents: - Extend of adhesions (1 = less than 1/3 of the uterine cavity involved with adhesions to 4 = more than 2/3 of the uterine cavity involved with adhesions),

    • Type of adhesions (1 = Filmy adhesions to 4 = dense adhesions)
    • Menstrual pattern (0= normal to 4 = amenorrhea).

    The final score allows the following prognostic classification:

    1-4 = mild disease, 5-8 = moderate disease 9-12 = severe disease

  2. Safety - Adverse Events

    Time frame: At second look hysteroscopy between 4 and 8 weeks

    Adverse events up to second look hysteroscopy.

Secondary outcomes

  1. High-responder Rate

    Time frame: At second look hysteroscopy between 4 and 8 weeks

    Percentage of patients who have improved from severe to mild adhesions or from severe to no adhesions or from moderate to no adhesions

  2. Change of "Extent of Cavity Involved" Component

    Time frame: At second look hysteroscopy between 4 and 8 weeks

    Average of AFS score component "extent of cavity involved"

  3. Change in "Extent of Cavity Involved" Component Between Post-adhesiolysis and Second Look Hysteroscopy

    Time frame: At second look hysteroscopy between 4 and 8 weeks

    Average of AFS score component "extent of cavity involved"

  4. AFS Score

    Time frame: At second look hysteroscopy between 4 and 8 weeks

    Average of AFS score

  5. Change of Extent of IUA AFS Score Component

    Time frame: At second look hysteroscopy between 4 and 8 weeks

    Average of the change of the AFS score component "Extent of IUA"

  6. Change of Type of IUA AFS Score Component

    Time frame: At second look hysteroscopy between 4 and 8 weeks

    Average of the change of the AFS score component "type of IUA"

  7. Menstrual Pattern AFS Score Component

    Time frame: At second look hysteroscopy between 4 and 8 weeks

    Average of the change of the AFS score component "Menstrual Pattern"

  8. Percentage of Patients Who Have Mild Adhesions or no Adhesion

    Time frame: At second look hysteroscopy between 4 and 8 weeks

    Percentage of patients who have AFS < 5

  9. Freedom From IUA

    Time frame: At second look hysteroscopy between 4 and 8 weeks

    Rate of patients who don't have adhesion

  10. ESGE Stage

    Time frame: At second look hysteroscopy between 4 and 8 weeks

    Rate of ECGE stage

  11. Level of Post-operative Pain

    Time frame: At second look hysteroscopy between 4 and 8 weeks

    Level of post-operative pain on a numeric rating scale, with 0 = no pain and 10 = the worst pain.

  12. Level of Discomfort Related to Vaginal Discharge

    Time frame: At second look hysteroscopy between 4 and 8 weeks

    Level of discomfort related to vaginal discharge on a numeric rating scale, with 0 = no discomfort and 10 = extremely disturbing

  13. Timing of Vaginal Discharge

    Time frame: At second look hysteroscopy between 4 and 8 weeks

    Timing of vaginal discharge as recalled by the patient

  14. Duration of the Vaginal Discharge

    Time frame: At second look hysteroscopy between 4 and 8 weeks

    Duration of the vaginal discharge as recalled by the patient

  15. Qualitative Description of the Vaginal Discharge

    Time frame: At second look hysteroscopy between 4 and 8 weeks

    Qualitative description of the vaginal discharge as recalled by the patient

  16. Change of Menstrual Pattern

    Time frame: At second look hysteroscopy between 4 and 8 weeks, 1 year, 2 years

    Change of menstrual pattern

  17. Reintervention Rate

    Time frame: At second look hysteroscopy or scheduled later up to one year

    Reintervention rate, during second look hysteroscopy or scheduled later up to one year

  18. Number of Adhesiolysis Procedures

    Time frame: After second look to one year

    Number of adhesiolysis procedures after second look to one year

  19. Pregnancy Rate

    Time frame: 1 year, 2 years, 3 years

    Pregnancy rate defined as presence of foetal sac or heartbeat by ultrasound at 1 year and 2 years, whether spontaneous or IVF

  20. Live Birth Rate

    Time frame: 1 year 2 years, 3 years

    Live birth rate at 1 year and 2 years

  21. Pregnancy Complication Rate

    Time frame: 3 years

    Pregnancy complication rate

  22. Time to Pregnancy

    Time frame: 3 years

    Time to pregnancy (i.e. time between the second look hysteroscopy and pregnancy start)

  23. IUA Severity According to Chinese Scoring System

    Time frame: At second look hysteroscopy between 4 and 8 weeks

    IUA severity according to Chinese scoring system (for patients enrolled in China only)

  24. Responder Rate

    Time frame: At second look hysteroscopy between 4 and 8 weeks

    Percentage of patients with an improvement of one clinical category i.e from Severe to Moderate or from Moderate to Mild

Sponsors and collaborators

Lead sponsor

Womed

Industry

Registry information

Acronym: PREG2

Important dates

Study start
2021
Primary completion
2023
Study completion
2026
First posted
Jul 15, 2021
Registry last updated
Mar 27, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.